[{"orgOrder":0,"company":"PentixaPharm","sponsor":"Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PentixaPharm \/ Pivotal S.L.","highestDevelopmentStatusID":"10","companyTruncated":"PentixaPharm \/ Pivotal S.L."},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"68-Ga Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ PentixaPharm","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ PentixaPharm"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"90-Y PentixaTher","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Elsa Eckert Life Science Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Elsa Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ Elsa Eckert Life Science Accelerator"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"Neuropeptide Y receptor type 2","graph1":"Oncology","graph2":"Preclinical","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ PentixaPharm","highestDevelopmentStatusID":"4","companyTruncated":"PentixaPharm \/ PentixaPharm"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"68-Ga PTF","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"BankM AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Y90-PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ BankM AG","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ BankM AG"}]

Find Clinical Drug Pipeline Developments & Deals by PentixaPharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lu177-PentixaTher is a novel radiopharmaceutical therapy, being investigated in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 21, 2024

                          Lead Product(s) : 177-Lu PentixaTher

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The proceeds will focus on the clinical development and approval of company's lead candidates Ga68-PentixaFor and Y90-PentixaTher.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 03, 2024

                          Lead Product(s) : Y90-PentixaTher

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : BankM AG

                          Deal Size : $22.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Through the acquisition, Pentixapharm will leverage the Glycotype portfolio of preclinical antibodies against multiple oncology including GT-001, which is being evaluated for breast and lung cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          July 03, 2024

                          Lead Product(s) : GT-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Glycotope

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : 90-Y PentixaTher is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Central Nervous System Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          November 15, 2023

                          Lead Product(s) : 90-Y PentixaTher

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : 68-Ga Pentixafor is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, B-Cell, Marginal Zone.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          November 09, 2023

                          Lead Product(s) : 68-Ga Pentixafor

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Pivotal S.L.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : 68-Ga PTF is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          February 03, 2022

                          Lead Product(s) : 68-Ga PTF

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : 68-Ga Pentixafor is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          October 26, 2021

                          Lead Product(s) : 68-Ga Pentixafor

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Memorial Sloan Kettering Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Undisclosed

                          February 06, 2020

                          Lead Product(s) : Pentixafor

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Elsa Eckert Life Science Accelerator

                          Deal Size : $16.2 million

                          Deal Type : Series A Financing

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Myelo001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Neutropenia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 26, 2016

                          Lead Product(s) : Myelo001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank